Elekta (STO:EKTA B) said yesterday it inked an 8-year strategic partnership with Australian radiotherapy provider GenesisCare for more than $100m.
The new partnership includes the acquisition of Elekta’s Leksell Gamma Knife Icon radiosurgery systems, Versa HD linear accelerators, brachytherapy systems, software and other services, Elekta said.
“We are proud to partner alongside GenesisCare and support their exciting vision. By choosing Elekta, GenesisCare will receive the most advanced and recognized cancer treatment solutions on the market. Both Leksell Gamma Knife and Versa HD are known for their extreme accuracy, efficiency and outstanding outcomes. We are looking forward to being GenesisCare’s partner as they expand into new markets,” CEO Tomas Puusepp said in prepared remarks.
GenesisCare will use the acquired products and solutions for its cancer treatment centers in Australia, the UK and “new markets,” the company said.
GenesisCare said it expects to order Elekta’s high-field 1.5 tesla MRI-guided linear accelerator when the technology is available on the market next year.
“Elekta is a natural partner for GenesisCare. We want all cancer patients to receive rapid access to high quality care. Elekta helps us make this happen with their suite of technology solutions, global reach and commitment to innovation. The MR-linac is a game changer. We expect cancer patients, including those receiving treatment for prostate, breast and other cancers, to benefit from this innovation. Anything that improves the accuracy of treatment and provides a smoother patient experience should improve outcomes,” managing directorDan Collins said in a press release.
